Sarcoma / 2015 / Article / Tab 2

Research Article

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 2

Adverse events occurring in more than 1 patient and all grade 3-4 adverse events.

Adverse eventGrade 2Grade 3Grade 4

Anemia1771
Neutropenia776
Leukopenia683
Hyperglycemia1231
Hypoalbuminemia131
Lymphopenia112
Thrombocytopenia145
Elevated ALT91
Elevated AST71
Fatigue 15
Hypophosphatemia23
Elevated alkaline phosphatase 22
Hypokalemia2
Edema 2
Diverticulitis1
Kidney stone1
Cellulitis1
Neck pain1
Pneumonia1
Mucositis 3
Hemorrhage, nose1
Perforation, GI-small bowel NOS1
Thrombosis/thrombus/embolism1

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.